Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5‐fluorouracil and folinic acid) versus Best Supportive Care in third or fourth line treatment of patients with metastatic colorectal cancer.
Epistemonikos ID: ab2964e3615b6f282cf2e4fef42dd6d9522428e3
First added on: May 21, 2024